Clinical Trials

Teva Pharmaceutical and Active Biotech announced that the results from the CONCERTO trial did not meet primary endpoint. The trial was based on patients with relapsing-remitting…
Read More...

Corvus Pharmaceuticals has expanded its clinical collaboration with Genentech. Under the new agreement, CPI-444 administered in combination with atezolizumab (Tecentriq) will be…
Read More...

SGS announced the successful completion of a Phase I clinical trial of a new strain of influenza virus in healthy volunteers. The study used a GMP-manufactured, non-hemagglutinating,…
Read More...

BioPharmX announced that it achieved primary endpoint in its phase 2b clinical trial evaluating BPX-011. From the topline results for the study's primary endpoint, BioPharmX…
Read More...

Propanc Biopharma provided an update on the development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for First-In-Human studies. PRP is a solution for…
Read More...

Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced the initiation of…
Read More...

Medicortex Finland Oy, a biotechnology company developing a diagnostic kit for brain injury detection based on a medical breakthrough biomarker, recently completed analyzing the results…
Read More...

Concert Pharmaceuticals announced the initiation of a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which…
Read More...

Neurotrope, Inc. announced positive top-line results from its Phase 2 study (-202 Study) of Bryostatin-1 in patients with moderate to severe Alzheimer's disease (AD), a population not…
Read More...

enGene announced that Theresa Podrebarac, has been appointed as the  Chief Medical Officer of the company. He will be responsible for designing and executing clinical development plan…
Read More...

TESARO an oncology-focused biopharmaceutical company, announced that following the recent identification of a fixed dose and patient-centric dosing schedule, the ongoing clinical trial…
Read More...

Merck announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with Merck’s strategy for its Healthcare business sector to focus…
Read More...

Savara Inc., a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare…
Read More...

Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)…
Read More...

Results from the phase 3 REPROVE study assessing Pfizer's fixed-dose antibacterial combo Zavicefta (ceftazidime-avibactam) in patients with hospital-acquired pneumonia (HAP)…
Read More...

Science 37 has raised $29m in Series C funding, led by Glynn Capital Management with participation from GV, to bring clinical trials directly into patients’ homes. The round included…
Read More...

Sutro Biopharma Inc named Crestovo CEO and COO Joseph M. Lobacki to its board of directors. Mr. Lobacki previously served as chief commercial officer of Medivation. He also served…
Read More...

CryoLife announced that the results from the On-X aortic heart valve PROACT study will be presented in a late-breaking session at the AATS (American Association for Thoracic Surgery)…
Read More...

Recipharm, the contract development and manufacturing organisation (CDMO), has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research…
Read More...

Novartis announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine. This agreement builds on a 2015…
Read More...